Skip to main content

Table 1 Baseline characteristics of hemodialysis patients on warfarin

From: Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management

 

Institution A

n = 20

Institution B

n = 30

P-value

Age, yrs

75.6

79.3

0.25

Male, n (%)

12 (60)

18 (60)

1

Comorbidities, n (%):

 CHF

11 (55)

17 (56.7)

0.91

 CAD

11 (55)

16 (53.3)

0.91

 DM (Type 2)

9 (45)

17 (56.7)

0.42

 CVA

8 (40)

8 (26.7)

0.32

 HTN

16 (80)

27 (90)

0.42

 Valvular A.Fib

5 (25)

6 (20)

0.74

HD Vintage, months (mean ± SD)

42.6 ± 39.6

50.8 ± 52.7

0.54

CHADS2 score (mean)

3.6

3.4

0.65

No. Hositalization events (mean)

0.8

1.13

0.27

Total duration of Hospitalization, days (mean ± SD)

10.9 ± 15.6

20 ± 36.4

0.23

Total duration of outpatient Antibiotic use, days (mean ± SD)

12.5 ± 26.0

27.1 ± 66.7

0.28

  1. CHF congestive heart failure, CAD coronary artery disease, HTN hypertension, DM Diabetes Mellitus, Valvular A.Fib atrial fibrillation with rheumatic mitral disease, mitral stenosis or prosthetic heart valves, HD hemodialysis